In the case of colon cancer cells, oxaliplatin increased HIF-2α accumulation and enhanced cell growth; indeed, HIF-2α may mediate, at least partly, oxaliplatin resistance in SW1116 cells.96 Disruption of HIF-1α or HIF-2α gene, or both, further improved the tumor response to sunitinib therapy in human colon cancer cells.97 Upregulation of HIF-2α induced by sorafenib was shown to contribute to resistance of hypoxic HCC cells by activating the TGF-α/EGFR pathway.79 This evidence concerns the gene EPAS1 and malignant colon neoplasm.